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Introduction
Lung cancer is the leading cause of cancer death in the United States, with over 160,000 deaths expected in 1997 (1) . Smoking causes at least 80% of lung cancer (2) . Therefore, smoking cessation is dearly the best way to decrease incidence and mortality from the great majority of lung This paper is based on a presentation at the symposium on Mechanisms Our approach to chemoprevention of lung cancer is based on an understanding of the carcinogens in tobacco smoke. Tobacco smoke is a complex mixture of compounds and contains at least 40 known carcinogens. Carcinogens identified in cigarette smoke include polynuclear aromatic hydrocarbons (PAHs), aza-arenes, which are PAHs containing a nitrogen in the ring system; nitrosamines; aromatic amines; aldehydes; miscellaneous organic compounds such as benzene, acrylonitrile, vinyl chloride, 2-nitropropane, and ethyl carbamate; and inorganic compounds such as hydrazine and various metals (4) . Among these, the PAHs and nitrosamines have in their families the strongest respiratory carcinogens, while certain aldehydes and metals are also known respiratory carcinogens. In contrast, some of the other carcinogens such as aromatic amines and benzene are associated with other cancers, such as bladder cancer and leukemia. The role of specific carcinogens of tobacco smoke in human cancers can be assessed by considering the amounts of the carcinogens in tobacco products, their target tissues and carcinogenic potency in laboratory animals, and biochemical evidence that humans and laboratory animals respond in similar ways. Likely causative agents for lung cancer are summarized in Table 1 (11) . DNA adducts specific to NNK and the related nitrosamine N'-nitrosonornicotine (NNN) have been detected in smokers' lungs, and metabolites of NNK are present in smokers' urine (10, 12) . Table 1 (16) (17) (18) (19) (20) .
With each cigarette, the smoker is exposed to PAHs and NNK. As illustrated in Figure 1 , these carcinogens undergo metabolic activation to DNA adducts. If these adducts persist unrepaired during DNA replication, miscoding can occur, leading to permanent mutations in critical genes such as p53 and ras, which are likely to be important in the lung cancer induction process. Blocking any one of these steps would decrease the probability of lung cancer development. Our strategy has been to block the metabolic activation step. This approach will be discussed in this report, using phenethyl isothiocyanate (PEITC), a chemopreventive agent against NNK-induced lung tumorigenesis, as one example, and benzyl isothiocyanate (BITC), an inhibitor of B[a]P-induced lung tumorigenesis, as another. Other known inhibitors of NNK-and B[a]Pinduced lung tumorigenesis will also be reviewed. We emphasize that the approach discussed here is only one example of strategies that can be employed for chemoprevention of lung cancer.
Inhibition of NNK-induced Lung Tumorigenesis by PEITC
A naturally occurring isothiocyanate, PEITC (PhCH2CH2N=C=S), is found as its glucosinolate conjugate gluconasturtiin in several vegetables including watercress. PEITC is released from watercress upon chewing by the action of myrosinase, a thioglucosidase present in the plant (21, 22 (25, 26) . Thus PEITC has been firmly established as an effective inhibitor of lung tumorigenesis induced by NNK in both rats and mice.
An overview of the major metabolic activation and detoxification pathways of NNK is illustrated in Figure 2 (27) . In laboratory animals and humans, NNK is rapidly converted to 4-(methylnitrosamino)-l - by carbonyl reductase enzymes. Also a potent pulmonary carcinogen, NNAL is partially converted to its diastereomeric glucuronides, [4- (29, 30) . In rats treated with PEITC by gavage or by addition to the diet, a persistent inhibition of metabolic activation of NNK is observed in lung microsomes, which results from inhibition of cytochrome P450 enzymes. In contrast, a persistent inhibition in liver microsomes is not observed. Experiments in vitro have shown that PEITC is a competitive inhibitor of NNK metabolic activation in rat lung microsomes, with the concentration that inhibits 50% ranging from 150 to 210 nM, and in explants of rat lung (30, 31) .
The effects of PEITC on NNK metabolism have also been examined in vivo. In these experiments, the goal was to determine whether the observed inhibition of tumorigenesis was due to 
Effects of Watercress Consumption on NNK Metabolism in Smokers
The studies described above demonstrate that PEITC inhibits NNK-induced lung tumorigenesis in rats and mice by inhibiting its metabolic activation. We wanted to determine whether similar effects would occur in smokers. The source of PEITC used in this study was watercress (Nasturtium officinale), which contains substantial amounts of gluconasturtiin, the glucosinolate precursor of PEITC (22) . Eleven smokers maintained constant smoking habits and avoided cruciferous vegetables and other sources of isothiocyanates throughout the study (82) . They donated 24-hr urine samples on 3 consecutive days (baseline period). After 1 to 3 days, they began the watercress consumption period, 3 days during which they consumed 2 oz (56.8 g) of watercress at each meal and donated 24-hr urine samples on each day. One and two weeks later they again donated 24-hr urine samples on 2 to 3 consecutive days (follow-up periods). The samples were analyzed for two metabolites of NNK; NNAL and NNAL-gluc, as well as N-acetyl-S-(N-phenethylthiocarbamoyl)-L-cysteine (PEITC-NAC), a metabolite of PEITC. Minimum exposure to PEITC during the watercress consumption period averaged 19 to 38 mg per day. Seven of the eleven subjects had increased levels of urinary NNAL plus NNAL-gluc on days 2 and 3 of the watercress consumption period, compared to the baseline period. Overall, the increase in urinary NNAL plus NNAL-gluc in this period was significant [mean ± SD, 0.924 ± 1.12 nmol/24 hr (33.5%), p< 0.0l]. Urinary levels of NNAL plus NNAL-gluc returned to near baseline levels in the follow-up periods. The percent increase in urinary NNAL plus NNAL-gluc during days 2 and 3 of the watercress consumption period correlated with PEITC intake during this period as measured by total urinary PEITC-NAC (r= 0.62, p= 0.04). The results of this study support our hypothesis that PEITC inhibits the oxidative metabolism of NNK in humans, as seen in rodents, and support further development of PEITC and other compounds as chemopreventive agents against lung cancer.
Summary
The research described in this paper conclusively demonstrates that a large number of compounds can inhibit the lung tumorigenicity of the important tobaccosmoke pulmonary carcinogens NNK and B[a]P in rodent models. Among Most of the inhibitors discussed in this paper must be present at the time of carcinogen administration to be effective, since in many cases they are inhibitors of metabolic activation or enhancers of carcinogen detoxification. This raises questions about their potential efficacy, depending on how tobacco carcinogenesis is viewed. Two models of tobacco carcinogenesis are outlined in Figure 3 . In the classical sequential model, initiation by compounds such as NNK or B[a]P is followed by promotion and progression. Tobacco smoke contains tumor promoters, and the partial reversibility of lung cancer risk associated with smoking cessation is consistent with the reversibility of promotion. However, this model may be somewhat unrealistic. Smokers are simultaneously exposed to carcinogens, promoters, cocarcinogens, and toxic compounds with every cigarette. Therefore, the chronic exposure model may be more realistic and is consistent with the concept that multiple genetic changes are involved in the carcinogenic process. These changes will be decreased by favorable alteration of several steps involved in carcinogenrelated gene changes (Figure 1 ). Protocols should be developed to identify agents that would be effective against all known steps in the lung-cancer induction process; typical animal data are summarized in Tables 5 and 6 , and by Moon et al. (84) . There is a clear need for identification of suppressing agents (compounds active after carcinogen exposure) in future studies, in part because there are a large number of ex-smokers who would benefit from chemoprevention. Such compounds would inhibit nongenotoxic aspects of lung carcinogenesis. Only a few suppressing agents are known at present that are active against lung tumors induced by tobacco smoke carcinogens. The further development of such agents should be a major research priority. 
